HealthDay Now: Alzheimer’s Drug Approval Harms FDA’s Reputation

In a HealthDay Now interview, we spoke with Dr. G. Caleb Alexander, a professor at Johns Hopkins. He served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Dr. Alexander discusses whether the FDA's reputation will take a permanent hit due to the drug's approval despite limited evidence of benefit.

HealthDay Now: Alzheimer’s Drug Approval Harms FDA’s Reputation


HealthDay Now